We have recently completed our Series B round, raising over $100m.
For investment-related inquiries, please contact Joseph Farmer, our Chief Operating Officer.
Xilio Therapeutics XTX101 (CTLA-4) Poster Presentation at SITC
Xilio Therapeutics XTX201 (IL-2) Poster Presentation at SITC
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC
Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Xilio Therapeutics Appoints Rachel Humphrey, M.D. to Board of Directors
Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors
Xilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
Xilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing
Akrevia Therapeutics Appoints Joseph Farmer as Chief Operating Officer
Akrevia Therapeutics Appoints René Russo, PharmD, as Chief Executive Officer
Akrevia Therapeutics Appoints Distinguished Research Leaders to Scientific Advisory Board
Akrevia Therapeutics Licenses Exclusive Rights from City of Hope to Expand Development Pipeline of Potent, Tumor Targeted Immunotherapies
Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture